^
    Back
    Association details:
    Biomarker:BTK C481S
    Cancer:Mantle Cell Lymphoma
    Drug:edralbrutinib (TG-1701) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2020
    Title:

    TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, cooperates with ublituximab-driven ADCC and ADCP in in vitro and in vivo models of ibrutinib-resistant mantle cell lymphoma

    Published date:
    05/13/2020
    Excerpt:
    When compared to ibrutinib, TG-1701 used at high doses retained notable antitumor activity in MCL cells with BTKC481S mutation.